Abstract
The current chapter discusses targeting macrophages with solid lipid nanoparticles (SLNs) loaded with drugs and genetic material. Macrophages are the key cells and play a crucial role in the maintenance of homeostasis, tissue maintenance, and also the immune system. Targeting macrophages to deliver drugs and genes is an important aspect in the development of delivery systems in the treatment of infections involving macrophages such as leishmaniasis, tuberculosis, and cancers related to lungs. Solid lipid nanoparticles (SLNs) are the emerging nanocarriers to deliver drugs and genes to the target cells, and the application of SLNs to deliver drugs and genetic materials to macrophages is a promising approach to follow. The properties of SLNs and various types of methods of preparation are discussed in this chapter along with the application of SLNs in targeting macrophages. Also, the current scenario of SLNs’ application for targeted therapy to enhance its targetability and internalization is discussed in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akbaba H, Akbaba GE, Kantarcı AG. Development and evaluation of antisense shRNA-encoding plasmid loaded solid lipid nanoparticles against 5-α reductase activity. J Drug Deliver Sci Tech. 2018;44:270–7. https://doi.org/10.1016/j.jddst.2018.01.001.
Apaolaza PS, Delgado D, del Pozo-Rodriguez A, Gascón AR, Solinís MÁ. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int J Pharm. 2014;465(1–2):413–26. https://doi.org/10.1016/j.ijpharm.2014.02.038.
Blasi P, Schoubben A, Traina G, et al. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int J Pharm. 2013;454(1):316–23. https://doi.org/10.1016/j.ijpharm.2013.06.037.
Calderon B, Suri A, Unanue ER. In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet β-cell killing: studies from an acute model. Am J Path. 2006;169(6):2137–47. https://doi.org/10.2353/ajpath.2006.060539.
Cannarile MA, Weisser M, Jacob W, Jegg A-M, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Imm Ther Cancer. 2017;5(1):53. https://doi.org/10.1186/s40425-017-0257-y.
Carrillo C, Sánchez-Hernández N, García-Montoya E, et al. DNA delivery via cationic solid lipid nanoparticles (SLNs). Eur J Pharm Sci. 2013;49(2):157–65. https://doi.org/10.1016/j.ejps.2013.02.011.
Chi H, Li C, Zhao FS, et al. Anti-tumor activity of toll-like receptor 7 agonists. Front Pharmacol. 2017;8:304. https://doi.org/10.3389/fphar.2017.00304.
Choi SH, Jin S-E, Lee M-K, et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm. 2008;68(3):545–54. https://doi.org/10.1016/j.ejpb.2007.07.011.
del Pozo-Rodríguez A, Delgado D, Solinís MÁ et al (2010) Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 385(1–2):157–162. https://doi.org/10.1016/j.ijpharm.2009.10.020.
Delgado D, Gascón AR, del Pozo-Rodríguez A, et al. Dextran–protamine–solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm. 2012;425(1–2):35–43. https://doi.org/10.1016/j.ijpharm.2011.12.052.
Dolatabadi JEN, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv Pharm Bullet. 2015;5(2):151. https://doi.org/10.15171/apb.2015.022.
dos Santos RB, Kanekiyo T, Singh J. In vitro and in vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA. Nano Med Nano Tech Biomed. 2020;102225 https://doi.org/10.1016/j.nano.2020.102225.
Fàbregas A, Sánchez-Hernández N, Ticó JR, et al. A new optimized formulation of cationic solid lipid nanoparticles intended for gene delivery: development, characterization and DNA binding efficiency of TCERG1 expression plasmid. Int J Pharm. 2014;473(1–2):270–9. https://doi.org/10.1016/j.ijpharm.2014.06.022.
Fan T, Chen C, Guo H, et al. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur J Pharm Biopharm. 2014;88(2):518–28. https://doi.org/10.1016/j.ejpb.2014.06.011.
Fernandes AV, Pydi CR, Verma R, Jose J, Kumar L. Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers. Brazilian J Pharm Sci. 2020;56:e18069. https://doi.org/10.1590/s2175-97902019000318069.
Gaspar DP, Faria V, Gonçalves LM, Taboada P, Remuñán-López C, Almeida AJ. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies. Int J Pharm. 2016;497(1–2):199–209. https://doi.org/10.1016/j.ijpharm.2015.11.050.
Gholamin S, Mitra SS, Feroze AH, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Trans Med. 2017;9(381) https://doi.org/10.1126/scitranslmed.aaf2968.
Gong C, Yu X, You B, et al. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. J Nano Biotech. 2020;18(1):1–17. https://doi.org/10.1186/s12951-020-00649-8.
Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol. 2007;59(7):935–40. https://doi.org/10.1211/jpp.59.7.0004.
He W, Kapate N, Shields CW IV, Mitragotri S. Drug delivery to macrophages: a review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv Drug Deliver Rev. 2020;165–166:15–40. https://doi.org/10.1016/j.addr.2019.12.001.
Hsu S-h YA, Yeh C-A, et al. Biocompatible nanogold carrier coated with hyaluronic acid for efficient delivery of plasmid or siRNA to mesenchymal stem cells. ACS App Biomaterial. 2019;2(3):1017–30. https://doi.org/10.1021/acsabm.8b00540.
Jin Y, Hu G, Guo M, et al. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation. Front Immun. 2019;10:1998. https://doi.org/10.3389/fimmu.2019.01998.
Kharaji MH, Doroud D, Taheri T, Rafati S. Drug targeting to macrophages with solid lipid nanoparticles harboring paromomycin: an in vitro evaluation against L. major and L. tropica. AAPS PharmSciTech. 2016;17(5):1110–9. https://doi.org/10.1208/s12249-015-0439-1.
Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release. 2004;99(2):259–69. https://doi.org/10.1016/j.jconrel.2004.07.006.
Kumar L, Reddy MS, Verma R, Koteshwara KB. Selection of cryoprotective agent for freeze drying of valsartan solid lipid nanoparticles. Latin Am J Pharm. 2016;35(2):284–90.
Liang Y, Wang Y, Wang L, et al. Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer. Bioact Material. 2021;6(2):433–46. https://doi.org/10.1016/j.bioactmat.2020.08.019.
Limeres MJ, Suñé-Pou M, Prieto-Sánchez S, et al. Development and characterization of an improved formulation of cholesteryl oleate-loaded cationic solid-lipid nanoparticles as an efficient non-viral gene delivery system. Colloid Surfac B. 2019;184:110533. https://doi.org/10.1016/j.colsurfb.2019.110533.
Lin PJ, Tam YYC, Hafez I, et al. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine: Nano Tech, Biol Med. 2013;9(2):233–46. https://doi.org/10.1016/j.nano.2012.05.019.
Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 2011;5(12):9977–83. https://doi.org/10.1021/nn203745n.
Ma C, Wu M, Ye W, et al. Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties. Drug Deliver Trans Res. 2020:1–18. https://doi.org/10.1007/s13346-020-00849-7.
Mahor S, Dash BC, O’Connor S, Pandit A. Mannosylated polyethyleneimine–hyaluronan nanohybrids for targeted gene delivery to macrophage-like cell lines. Bioconjug Chem. 2012;23(6):1138–48. https://doi.org/10.1021/bc200599k.
Makled S, Nafee N, Boraie N. Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. Int J Pharm. 2017;517(1–2):312–21. https://doi.org/10.1016/j.ijpharm.2016.12.026.
Mannucci S, Boschi F, Cisterna B, et al. A correlative imaging study of in vivo and ex vivo biodistribution of solid lipid nanoparticles. Int J Nanomedicine. 2020;15:1745. https://doi.org/10.2147/IJN.S236968.
Maretti E, Costantino L, Buttini F, et al. Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy. Drug Deliver Trans Res. 2019;9(1):298–310. https://doi.org/10.1007/s13346-018-00607-w.
Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto E, Ferreira D. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1–2):216–27. https://doi.org/10.1016/j.ijpharm.2012.03.032.
Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm. 2013;85(3):488–502. https://doi.org/10.1016/j.ejpb.2013.08.011.
Meng K, Chen D, Yang F, et al. Intracellular delivery, accumulation, and discrepancy in antibacterial activity of four enrofloxacin-loaded fatty acid solid lipid nanoparticles. Colloid Surfac B. 2020;194:111196. https://doi.org/10.1016/j.colsurfb.2020.111196.
Montana G, Bondì ML, Carrotta R, et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug Chem. 2007;18(2):302–8. https://doi.org/10.1021/bc0601166.
Nally FK, De Santi C, McCoy CE. Nanomodulation of macrophages in multiple sclerosis. Cell. 2019;8(6):543. https://doi.org/10.3390/cells8060543.
Olbrich C, Bakowsky U, Lehr C-M, Müller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 2001;77(3):345–55. https://doi.org/10.1016/S0168-3659(01)00506-5.
Parvez S, Yadagiri G, Gedda MR, et al. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Report. 2020;10(1):1–14. https://doi.org/10.1038/s41598-020-69276-5.
Peterson KR, Cottam MA, Kennedy AJ, Hasty AH. Macrophage-targeted therapeutics for metabolic disease. Trend Pharmcol Sci. 2018;39(6):536–46. https://doi.org/10.1016/j.tips.2018.03.001.
Pires VC, Magalhães CP, Ferrante M, et al. Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: preparation, characterization and macrophage uptake. Acta Trop. 2020;211:105595. https://doi.org/10.1016/j.actatropica.2020.105595.
Qi J, Lu Y, Wu W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Cur Drug Met. 2012;13(4):418–28. https://doi.org/10.2174/138920012800166526.
Qiu S-Q, Waaijer SJ, Zwager MC, de Vries EG, van der Vegt B, Schröder CP. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treatment Review. 2018;70:178–89. https://doi.org/10.1016/j.ctrv.2018.08.010.
Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–59. https://doi.org/10.1016/j.ccr.2014.05.016.
Rudolph C, Schillinger U, Ortiz A, et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res. 2004;21(9):1662–9. https://doi.org/10.1023/B:PHAM.0000041463.56768.ec.
Soni MP, Shelkar N, Gaikwad RV, Vanage GR, Samad A, Devarajan PV. Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis. J Pharm Bioallied Sci. 2014;6(1):22. https://doi.org/10.4103/0975-7406.124309.
Sun P, Zhong M, Shi X, Li Z. Anionic LPD complexes for gene delivery to macrophage: preparation, characterization and transfection in vitro. J Drug Target. 2008;16(9):668–78. https://doi.org/10.1080/10611860802201381.
Suñé-Pou M, Prieto-Sánchez S, El Yousfi Y, et al. Cholesteryl oleate-loaded cationic solid lipid nanoparticles as carriers for efficient gene-silencing therapy. Int J Nano Med. 2018;13:3223. https://doi.org/10.2147/IJN.S158884.
Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr C-M. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm. 2004;57(2):155–62. https://doi.org/10.1016/j.ejpb.2003.10.015.
Vaghasiya H, Kumar A, Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci. 2013;49(2):311–22. https://doi.org/10.1016/j.ejps.2013.03.013.
Van Lent P, Holthuysen A, Van Rooijen N, Van De Putte L, Van Den Berg W. Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis. Ann Rheum Dis. 1998;57(7):408–13. https://doi.org/10.1136/ard.57.7.408.
Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheum. 2013;9(3):164. https://doi.org/10.1038/nrrheum.2013.4.
Veremeyko T, Yung AW, Dukhinova M, et al. Cyclic AMP pathway suppress autoimmune neuroinflammation by inhibiting functions of encephalitogenic CD4 T cells and enhancing M2 macrophage polarization at the site of inflammation. Front Immun. 2018;9:50. https://doi.org/10.3389/fimmu.2018.00050.
Vieira AC, Chaves LL, Pinheiro M, et al. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Art Cells Nano Med Biotech. 2018;46(1):653–63. https://doi.org/10.1080/21691401.2018.1434186.
Vighi E, Montanari M, Ruozi B, Tosi G, Magli A, Leo E. Nuclear localization of cationic solid lipid nanoparticles containing protamine as transfection promoter. Eur J Pharm Biopharm. 2010;76(3):384–93. https://doi.org/10.1016/j.ejpb.2010.07.012.
Wang J, Zhu R, Sun D, et al. Intracellular uptake of curcumin-loaded solid lipid nanoparticles exhibit anti-inflammatory activities superior to those of curcumin through the NF-κB signaling pathway. J Biomed Nan Tech. 2015;11(3):403–15. https://doi.org/10.1166/jbn.2015.1925.
Yarilina A, Xu K, Chan C, Ivashkiv LB. Regulation of inflammatory responses in tumor necrosis factor–activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arth Rheum. 2012;64(12):3856–66. https://doi.org/10.1002/art.37691.
Ye J, Wang A, Liu C, Chen Z, Zhang N. Anionic solid lipid nanoparticles supported on protamine/DNA complexes. Nano Tech. 2008;19(28):285708. https://doi.org/10.1088/0957-4484/19/28/285708.
Ying B, Campbell RB. Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculature. Biochem Biophys Res Comm. 2014;446(2):441–7. https://doi.org/10.1016/j.bbrc.2014.02.120.
Yu W, Liu C, Ye J, Zou W, Zhang N, Xu W. Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery. Nano Tech. 2009;20(21):215102. https://doi.org/10.1088/0957-4484/20/21/215102.
Yu W, Liu C, Liu Y, Zhang N, Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;27(8):1584–96. https://doi.org/10.1007/s11095-010-0149-z.
Zakirov FH, Zhang D, Grechko AV, Wu WK, Poznyak AV, Orekhov AN. Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy. Pharmacol Res Perspect. 2020;8(2):e00584. https://doi.org/10.1002/prp2.584.
Zeisberger S, Odermatt B, Marty C, Zehnder-Fjällman A, Ballmer-Hofer K, Schwendener R. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95(3):272–81. https://doi.org/10.1038/sj.bjc.6603240.
Zhan X, Jia L, Niu Y, et al. Targeted depletion of tumour-associated macrophages by an alendronate–glucomannan conjugate for cancer immunotherapy. Biomaterials. 2014;35(38):10046–57. https://doi.org/10.1016/j.biomaterials.2014.09.007.
Zhou M, Hou J, Zhong Z, Hao N, Lin Y, Li C. Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug Deliver. 2018;25(1):716–22. https://doi.org/10.1080/10717544.2018.1447050.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jitta, S.R., Kumar, L. (2022). Solid Lipid Nanoparticles-Based Drug and Gene Delivery to Macrophages. In: Gupta, S., Pathak, Y.V. (eds) Macrophage Targeted Delivery Systems. Springer, Cham. https://doi.org/10.1007/978-3-030-84164-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-84164-5_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84163-8
Online ISBN: 978-3-030-84164-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)